In this context, a critical role for IL-36γ and IL-36Ra in gut inflammation and tumorigenesis has been demonstrated, proposing that targeting the IL-36γ/IL-36R signalling balance may offer a potential therapeutic strategy for inflammatory bowel disease and gastrointestinal cancers [24]. Here, IL1RL2 is linked to inflammatory bowel disease.